Fidelity Investments
NEUP

Fidelity Investments’s Neuphoria Therapeutics NEUP Stock Holding History

Fidelity Investments’s Portfolio NEUP Stock Details NEUP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2
Closed -$24 – 5654
2025
Q3 		$24 Buy
+2
New +$19 ﹤0.01% 5308

Other funds holding NEUP

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.4% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Fidelity Investments's NEUP Position: Q4 2025 in Review

Fidelity Investments sold out of Neuphoria Therapeutics (NEUP) in Q4 2025, closing a stake of 2 shares — an estimated $24 sold.

Fidelity Investments first reported a position in NEUP in Q3 2025 and held it in 1 quarter. The position peaked at $24 in Q3 2025. 21 funds tracked by Wall St. Rank hold NEUP as of Q4 2025.

  • Fidelity Investments reported no remaining Neuphoria Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Fidelity Investments sold 2 Neuphoria Therapeutics shares in Q4 2025, an estimated $24.
  • Fidelity Investments first reported a position in Neuphoria Therapeutics in Q3 2025 and held it in 1 quarter.
  • Fidelity Investments's Neuphoria Therapeutics position peaked at $24 in Q3 2025.
  • 21 funds tracked by Wall St. Rank held Neuphoria Therapeutics as of Q4 2025.

Based on Fidelity Investments's 13F filing for Q4 2025, filed 17 Feb 2026.